Taken from American Family Physician at the following website:
http://www.aafp.org/afp/20020615/2525.html
Aricept and Namenda

Unfortunately, not all doctors are aware of the major improvement we can experience when namenda (memantine) is started early, along with the aricept.  I've copied two references below that you can print out to show to your doctor.  I feel so very badly when I hear of people who are not given the chance of benefitting from their use. 

Ebixa® * (Namenda in the States)

What is Ebixa® (memantine hydrochloride) and what is its promise?

This story has to start by talking about another neurotransmitter called "glutamate," quite different from acetylcholine in that it's not destroyed by an enzyme after doing its job of conveying the message across the junctions between nerve cells.

Instead it's taken back up into the nerve endings from which it was released (recycled). This uptake requires that the glutamate combines first with special receiving molecules on the nerve endings called glutamate receptors (also known as "NMDA receptors").

However, there's a twist to the story here. All the cells of the body contain a lot of glutamate because it has important metabolic roles aside from being a neurotransmitter. When cells get sick (any cells) this glutamate leaks out, and in the nervous system the levels that glutamate can reach outside sick nerve cells can be so high as to be toxic, indeed quite deadly. This is one of the reasons nerve cells die in Alzheimer's disease -- their sickness could be mild, but the glutamate leakage multiplies the threat.

Memantine acts by blocking the glutamate receptors and preventing the re-uptake of the glutamate into the nerve endings. Since the glutamate threat develops somewhat late in Alzheimer's disease, memantine stands as one treatment that can be effective at moderate to advanced stages of the disease. The beauty of this approach is that the drug allows enough glutamate to get back for the sick nerve endings to use it as a transmitter, but prevents the massive uptake that would be toxic to the endings.

And there is better news: ongoing research is finding that combining cholinesterase inhibitors together with memantine seems to greatly improve the outcome, more than predicted from the sum of the effects of either drug alone. So combination therapy seems likely to become an exciting therapeutic approach in the future.

[The contents of this page are provided for information purposes only and do not represent advice, an endorsement or a recommendation, with respect to any product, service or enterprise, and/or the claims and properties thereof, by the Alzheimer Society of Canada. The information contained in this report was current at the time of printing, October 2005.]

Proven Benefits

Combination Therapy with Namenda
May Help Improve Quality of Life

With Alzheimer's disease, each patient is unique – and the treatment needs of each person with the disease will change over time. Although the person you are caring for is already on treatment, you may be wondering if more can be done to treat his or her symptoms. In some cases, combination therapy with Namenda® (memantine HCl)  may offer additional benefits and may be an appropriate option.

Namenda + Aricept

The results of a clinical trial published in the Journal of the American Medical Association showed Alzheimer's patients taking Namenda in combination with Aricept® (donepezil) experienced a slower rate of decline in thinking, function and behavior compared to those taking Aricept alone. 

The study found that combination therapy with Namenda+Aricept may:

  • Improve and maintain thinking
  • Help maintain the ability to perform activities of daily living such as grooming, finding belongings and conversing
  • Significantly improve behavior
  • Delay the onset of negative behavioral symptoms such as agitation, aggression and irritability in asymptomatic people

By treating the symptoms of Alzheimer's disease, Namenda, in combination with Aricept, may do more to treat the symptoms of the disease and allow people with Alzheimer's to recognize and interact with family and friends longer and may help make life more manageable for everyone involved.

Behavior & Mood Disorder drugs


Treatment of Behavior and Mood Disorders


Antipsychotic drugs
Atypical antipsychotic agents
  Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness
  General cautions: diminished risk of developing extrapyramidal symptoms and tardive dyskinesia compared with typical antipsychotic agents
  Risperidone (Risperdal) Initial dosage: 0.25 mg per day at bedtime;maximum: 2 to 3 mg per day, usually twice daily in divided doses Comments: current research supports use of low dosages; extrapyramidal symptoms may occur at 2 mg per day.
  Olanzapine (Zyprexa) Initial dosage: 2.5 mg per day at bedtime; maximum: 10 mg per day, usually twice dailyin divided doses Comments: generally well tolerated
  Quetiapine (Seroquel) Initial dosage: 12.5 mg twice daily; maximum: 200 mg twice daily Comments: more sedating; beware of transient orthostasis.
Typical antipsychotic agents
  Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; second-line therapy in patients who cannot tolerate or do not respond to atypical antipsychotic agents
  General cautions: current research suggests that these drugs should be avoided if possible, because they are associated with significant, often severe side effects involving the cholinergic, cardiovascular, and extrapyramidal systems; there is also an inherent risk of irreversible tardive dyskinesia, which can develop in 50% of elderly patients after continuous use of typical antipsychotic agents for 2 years.
  Haloperidol (Haldol), fluphenazine (Prolixin), thiothixene (Navane) Dosage: varies by agent Comments: anticipated extrapyramidal symptoms; if these symptoms occur, decrease dosage or switch to another agent; avoid use of benztropine (Cogentin) or trihexyphenidyl (Artane).
  Trifluoperazine (Stelazine), molindone (Moban), perphenazine (Trilafon), loxapine (Loxitane) Dosage: varies by agent Comments: agents with "in-between" side effect profile
Mood-stabilizing (antiagitation) drugs
  Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; useful alternatives to antipsychotic agents for control of severe agitated, repetitive, and combative behaviors
  General cautions: see comments about specific agents.
  Trazodone (Desyrel) Initial dosage: 25 mg per day; maximum: 200 to 400 mg per day in divided doses Comments: use with caution in patients with premature ventricular contractions.
  Carbamazepine (Tegretol) Initial dosage: 100 mg twice daily; titrate totherapeutic blood level (4 to 8 mcg per mL) Comments: monitor complete blood cell count and liver enzyme levels regularly; carbamazepine has problematicside effects.
  Divalproex sodium (Depakote) Initial dosage: 125 mg twice daily; titrate to therapeutic blood level (40 to 90 mcg per mL) Comments: generally better tolerated than other mood stabilizers; monitor liver enzyme levels; monitor platelets, prothrombin time, and partial thromboplastin time as indicated.
Anxiolytic drugs
Benzodiazepines
  Recommended uses: management of insomnia, anxiety, and agitation
  General cautions: regular use can lead to tolerance, addiction, depression, and cognitive impairment; paradoxic agitation occurs in about 10% of patients treated with benzodiazepines; infrequent, low doses of agents with a short half-life are least problematic.
  Lorazepam (Ativan), oxazepam (Serax), temazepam (Restoril), zolpidem (Ambien), triazolam (Halcion) Dosage: varies by agent See general cautions.
Nonbenzodiazepines
  Buspirone (BuSpar) Initial dosage: 5 mg twice daily; maximum: 20 mg three times daily Comments: useful only in patients with mild to moderate agitation; may take 2 to 4 weeks to become effective
Antidepressant drugs
  Recommended uses: see comments on specific agents.
  General cautions: selection of an antidepressant is usually based on previous treatment response, tolerance, and the advantage of potential side effects (e.g., sedation versus activation); a full therapeutic trial requires at least 4 to 8 weeks; as a rule, dosage is increased using increments of initial dose every 5 to 7 days until therapeutic benefits or significant side effects become apparent; after 9 months, dosage reduction is used to reassess the need to medicate; discontinuing an antidepressant over 10 to 14 days limits withdrawal symptoms.
NOTE:
Patients with depression and psychosis require concomitant antipsychotic medication.
Tricyclic antidepressant agents
  Desipramine (Norpramin) Initial dosage: 10 to 25 mg in the morning; maximum: 150 mg in the morning Comments: tends to be activating (i.e., reduces apathy); lower risk for cardiotoxic, hypotensive, and anticholinergiceffects; may cause tachycardia; blood levels may be helpful.
  Nortriptyline (Pamelor) Initial dosage: 10 mg at bedtime; anticipated dosage range: 10 to 40 mg per day (given twice daily) Comments: tolerance profile is similar to that for desipramine, but nortriptyline tends to be more sedating; may be useful in patients with agitated depression and insomnia; therapeutic blood level "window" of 50 to 150 ng per mL (190 to 570 nmol per L)
Heterocyclic and noncyclic antidepressant agents
  Nefazodone (Serzone) Initial dosage: 50 mg twice daily; maximum: 150 to 300 mg twice daily Comments: effective, especially in patients with associatedanxiety; reduce dose of coadministered alprazolam (Xanax) or triazolam by 50%; monitor for hepatotoxicity.
  Bupropion (Wellbutrin) Initial dosage: 37.5 mg every morning, then increase by 37.5 every 3 days; maximum: 150 mg twice daily Comments: activating; possible rapid improvement of energylevel; should not be used in agitated patients and those with seizure disorders; to minimize risk of insomnia, give second dose before 3 p.m.
  Mirtazapine (Remeron) Initial dosage: 7.5 mg at bedtime; maximum: 30 mg at bedtime Comments: potent and well tolerated; promotes sleep, appetite, and weight gain